{"product_id":"pharmacotherapy-of-child-and-adolescent-psychiatric-disorders-hardback-9780470973769","title":"Pharmacotherapy of Child and Adolescent Psychiatric Disorders (Hardback) 9780470973769","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003ePharmacotherapy of Child and Adolescent Psychiatric Disorders\u003c\/font\u003e\u003cbr\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003c\/p\u003e\n\u003cp\u003e\u003cfont size=\"4\"\u003eDavid Rosenberg (Edited by), Samuel Gershon (Edited by)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9780470973769, Wiley\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eHardback, published 3 February 2012\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e480 pages\u003cbr\u003e25.2 x 17.8 x 2.8 cm, 0.871 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cem\u003e\u003cfont size=\"3\"\u003e\u003cp\u003e “Pharmacotherapy of Child and Adolescent Psychiatric Disorders is a book to have available on your desk, not just in your library.  It provides ready access to the wealth of practical information and insight for the range of health and mental health professionals.  It is highly recommended for trainees and anyone who is prescribing psychotropic medications to the pediatric population and young adults.”  (\u003ci\u003eJournal of Clinical Psychiatry\u003c\/i\u003e, 7 July 2012)\u003c\/p\u003e \u003cp\u003e \u003c\/p\u003e \u003cp\u003e \u003c\/p\u003e \u003cp\u003e \u003c\/p\u003e\u003c\/font\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003eThis book fulfils an urgent need for an updated text on pediatric psychopharmacology. It takes a unique approach in discussing recent findings within the context of current issues, including economic and political ones. The book covers the emerging question of treating children who do not yet meet diagnostic criteria for psychosis, e.g, schizophrenia or bipolar disorder, but who are deemed to be at high risk. This is an active area of debate: such children are being treated in certain centers, while others reject this completely. The book addresses the antidepressant controversy, the placebo response and unique strategies for delineating this, and ways to optimize the differential between active medication and placebo. It reviews the impact of recent American Heart Association guidelines for monitoring children on stimulants and other psychotropics. It adheres closely to DSM-IV diagnostic criteria throughout. The book describes the use of newly approved drugs such as Lexapro for treating adolescent depression and the novel compound Intuniv. It covers the TADS and CAMS studies, which evaluated the use of SSRIs alone and in combination with cognitive behavioral therapy for adolescent depression. Other topics include treatment of bipolar disorders, the increasing popularity of generic equivalents, combination pharmacotherapy and the potential dangers of psychotropic medications.  \u003cul\u003e \u003cli\u003eThird edition of the first ever book published on pediatric psychopharmacology from renowned editors.\u003c\/li\u003e \u003cli\u003eIncorporates current developments with regard to SSRIs, their indications and their safety issues, including possible associated suicidal behavior.\u003c\/li\u003e \u003cli\u003eAddresses concerns about cardiovascular side effects of the new stimulant medications available, and compares to other FDA-approved medications for ADHD.\u003c\/li\u003e \u003cli\u003eFeatures many tables, figures and pictorials, making it highly accessible and reader friendly.\u003c\/li\u003e \u003c\/ul\u003e\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eList of Contributors, xv  \u003cp\u003eForeword, xix\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 1 Historical Perspectives on Child and Adolescent Psychopharmacology, 1\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eSamuel Gershon\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eReferences, 4\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 2 Pharmacoepidemiology of Psychotropic Medications in Youth, 7\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eDaniel J. Safer \u0026amp; Julie Magno Zito\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction, 7\u003c\/p\u003e \u003cp\u003ePrevalence and trends for medications prescribed for ADHD, 8\u003c\/p\u003e \u003cp\u003eNonstimulant medications for ADHD, 11\u003c\/p\u003e \u003cp\u003eAntidepressant medication, 11\u003c\/p\u003e \u003cp\u003eAntipsychotic medication, 13\u003c\/p\u003e \u003cp\u003eAlpha-agonists, 14\u003c\/p\u003e \u003cp\u003eAnticonvulsant \"mood stabilizers\", 15\u003c\/p\u003e \u003cp\u003eConcomitant psychotropic medication, 15\u003c\/p\u003e \u003cp\u003ePreschool psychotropic medication use, 17\u003c\/p\u003e \u003cp\u003eInternational patterns of psychotropic medication for youth, 17\u003c\/p\u003e \u003cp\u003eConclusion, 18\u003c\/p\u003e \u003cp\u003eReferences, 18\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 3 Off-Label Prescribing of Drugs in Child and Adolescent Psychiatry, 25\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eC. Lindsay DeVane\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction, 25\u003c\/p\u003e \u003cp\u003eExtent of off-label prescribing, 27\u003c\/p\u003e \u003cp\u003eNeed for psychoactive drug treatments for children and adolescents, 31\u003c\/p\u003e \u003cp\u003eLegislation supporting pediatric drug development, 33\u003c\/p\u003e \u003cp\u003eRecommendations to follow when considering off-label prescribing, 35\u003c\/p\u003e \u003cp\u003eReferences, 36\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 4 The Use of Generic Drugs in Pediatric Psychopharmacology, 39\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eRichard I. Shader \u0026amp; Christopher-Paul Milne\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eWhat is a generic drug?, 39\u003c\/p\u003e \u003cp\u003eWhy are we discussing generic drugs?, 39\u003c\/p\u003e \u003cp\u003eBasic requirements for generic drugs, 40\u003c\/p\u003e \u003cp\u003eThe status of regulations regarding generic drugs and children, 41\u003c\/p\u003e \u003cp\u003eAbbreviated new drug application (ANDA) requirements, 42\u003c\/p\u003e \u003cp\u003ePediatric assessments of adult drugs (history up to current status), 43\u003c\/p\u003e \u003cp\u003eBest Pharmaceuticals for Children Act, 44\u003c\/p\u003e \u003cp\u003ePediatric Research Equity Act, 45\u003c\/p\u003e \u003cp\u003eIntersection of requirements for generics and pediatric assessment, 46\u003c\/p\u003e \u003cp\u003eFuture directions, 48\u003c\/p\u003e \u003cp\u003eConcluding thoughts, 49\u003c\/p\u003e \u003cp\u003eReferences, 49\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 5 Psychoactive Drug Use in Children: Basic Concepts in Clinical Pharmacology, 51\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eDavid J. Edwards\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction, 51\u003c\/p\u003e \u003cp\u003eBasic concepts in pharmacokinetics, 52\u003c\/p\u003e \u003cp\u003eDosing considerations for psychoactive drugs in children, 55\u003c\/p\u003e \u003cp\u003eSummary, 60\u003c\/p\u003e \u003cp\u003eReferences, 60\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 6 Psychostimulants, 65\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eSteven R. Pliszka\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction, 65\u003c\/p\u003e \u003cp\u003eEpidemiology of stimulant use, 66\u003c\/p\u003e \u003cp\u003eStructure and biochemical mechanism of action, 66\u003c\/p\u003e \u003cp\u003eNeuroimaging studies of stimulant effects, 67\u003c\/p\u003e \u003cp\u003eStudies of short-term efficacy, 72\u003c\/p\u003e \u003cp\u003eStudies of long-term efficacy, 76\u003c\/p\u003e \u003cp\u003eClinical use, 79\u003c\/p\u003e \u003cp\u003eCommon side-effects, 84\u003c\/p\u003e \u003cp\u003eCardiovascular safety issues, 86\u003c\/p\u003e \u003cp\u003eGrowth suppression, 88\u003c\/p\u003e \u003cp\u003eSubstance use and diversion, 88\u003c\/p\u003e \u003cp\u003eComparison with nonstimulant treatment, 89\u003c\/p\u003e \u003cp\u003eTreatment of comorbidity, 92\u003c\/p\u003e \u003cp\u003ePharmacogenetics, 93\u003c\/p\u003e \u003cp\u003eConclusions, 94\u003c\/p\u003e \u003cp\u003eReferences, 94\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 7 Tricyclic Antidepressants and Monoamine Oxidase Inhibitors for the Treatment of Child and Adolescent Psychiatric Disorders, 105\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eCharlotte M. Heleniak, Tejal Kaur, Kareem D. Ghalib \u0026amp; Moira A. Rynn\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eTricyclic antidepressants (TCAs), 105\u003c\/p\u003e \u003cp\u003eDrug interactions, contraindications, 116\u003c\/p\u003e \u003cp\u003eMonoamine oxidase inhibitors (MAOIs), 117\u003c\/p\u003e \u003cp\u003eGeneral summary, 122\u003c\/p\u003e \u003cp\u003eReferences, 123\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 8 Selective Serotonin Reuptake Inhibitors (SSRIs), 131\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eDara Sakolsky \u0026amp; Boris Birmaher\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003ePharmacokinetics, 131\u003c\/p\u003e \u003cp\u003eInitiation and titration, 133\u003c\/p\u003e \u003cp\u003eIndications and efficacy, 134\u003c\/p\u003e \u003cp\u003eAdverse effects, 146\u003c\/p\u003e \u003cp\u003eWithdrawal, 149\u003c\/p\u003e \u003cp\u003eReferences, 149\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 9 Novel (Atypical) Antidepressants, 155\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eHeidi R. Bruty, Graham J. Emslie \u0026amp; Paul Croarkin\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eNovel (atypical) antidepressants, 155\u003c\/p\u003e \u003cp\u003eGeneral overview, 155\u003c\/p\u003e \u003cp\u003eBupropion, 157\u003c\/p\u003e \u003cp\u003eDuloxetine, 162\u003c\/p\u003e \u003cp\u003eMirtazapine, 164\u003c\/p\u003e \u003cp\u003eTrazodone, 166\u003c\/p\u003e \u003cp\u003eVenlafaxine, 170\u003c\/p\u003e \u003cp\u003eDesvenlafaxine, 173\u003c\/p\u003e \u003cp\u003eAlternative treatments, 174\u003c\/p\u003e \u003cp\u003eSummary, 175\u003c\/p\u003e \u003cp\u003eReferences, 176\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 10 Antipsychotic Agents, 181\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eBrieana M. Rowles, John L. Hertzer \u0026amp; Robert L. Findling\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction, 181\u003c\/p\u003e \u003cp\u003eChemical properties, 182\u003c\/p\u003e \u003cp\u003eTypical antipsychotics, 183\u003c\/p\u003e \u003cp\u003eAtypical antipsychotics, 186\u003c\/p\u003e \u003cp\u003eEthical issues: treatment of at-risk populations, 212\u003c\/p\u003e \u003cp\u003eConclusions, 213\u003c\/p\u003e \u003cp\u003eReferences, 213\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 11 Lithium, 221\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eGarrett M. Sparks \u0026amp; David A. Axelson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction, 221\u003c\/p\u003e \u003cp\u003ePharmacology, 222\u003c\/p\u003e \u003cp\u003ePotential mechanisms of action, 222\u003c\/p\u003e \u003cp\u003eEvidence for the use of lithium in children and adolescents, 232\u003c\/p\u003e \u003cp\u003eDosing and drug monitoring, 239\u003c\/p\u003e \u003cp\u003eContraindications, precautions, and drug interactions, 242\u003c\/p\u003e \u003cp\u003eSide-effects, 246\u003c\/p\u003e \u003cp\u003eReferences, 250\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 12 Anticonvulsants Used in Child and Adolescent Psychiatric Disorders, 261\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eMani Pavuluri \u0026amp; Tushita Mayanil\u003cbr\u003e \u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction, 261\u003c\/p\u003e \u003cp\u003eDivalproex sodium, 261\u003c\/p\u003e \u003cp\u003eCarbamazepine, 271\u003c\/p\u003e \u003cp\u003eOxcarbazepine, 275\u003c\/p\u003e \u003cp\u003eLamotrigine, 279\u003c\/p\u003e \u003cp\u003eGabapentin, 284\u003c\/p\u003e \u003cp\u003eTopiramate, 285\u003c\/p\u003e \u003cp\u003eConclusion, 288\u003c\/p\u003e \u003cp\u003eReferences, 288\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 13 Anxiolytics, 301\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eBarbara J. Coffey \u0026amp; Amanda L. Zwilling\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChemical properties, 301\u003c\/p\u003e \u003cp\u003eIndications, 305\u003c\/p\u003e \u003cp\u003eContraindications, 320\u003c\/p\u003e \u003cp\u003eAdverse effects, 321\u003c\/p\u003e \u003cp\u003eOverdose, 324\u003c\/p\u003e \u003cp\u003eAbuse\/dependence, 324\u003c\/p\u003e \u003cp\u003eDrug interactions, 325\u003c\/p\u003e \u003cp\u003eAvailable preparations and cost, 325\u003c\/p\u003e \u003cp\u003eInitiation and maintenance of treatment, 325\u003c\/p\u003e \u003cp\u003eManagement of specific side-effects, 330\u003c\/p\u003e \u003cp\u003eHow to withdraw medication, 332\u003c\/p\u003e \u003cp\u003eReferences, 332\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 14 Adrenergic Agents in Child and Adolescent Psychiatry, 341\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eLawrence David Scahill\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eClonidine and guanfacine, 341\u003c\/p\u003e \u003cp\u003eGuanfacine, 349\u003c\/p\u003e \u003cp\u003eBeta-blockers, 355\u003c\/p\u003e \u003cp\u003eAcknowledgements, 361\u003c\/p\u003e \u003cp\u003eReferences, 361\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 15 Atypical Psychopharmacologic Strategies, 365\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eJess Shatkin \u0026amp; Aron Janssen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eOpiate antagonists, 365\u003c\/p\u003e \u003cp\u003eMemantine, 368\u003c\/p\u003e \u003cp\u003eRiluzole, 369\u003c\/p\u003e \u003cp\u003eSecretin, 371\u003c\/p\u003e \u003cp\u003eTopiramate, 372\u003c\/p\u003e \u003cp\u003eHerbal medications and dietary supplements, 373\u003c\/p\u003e \u003cp\u003eGinkgo (\u003ci\u003eGinkgo biloba\u003c\/i\u003e), 375\u003c\/p\u003e \u003cp\u003eMelatonin, 381\u003c\/p\u003e \u003cp\u003eOmega-3 fatty acids, 383\u003c\/p\u003e \u003cp\u003eSt. John's wort (\u003ci\u003eHypericum perforatum\u003c\/i\u003e), 384\u003c\/p\u003e \u003cp\u003eValerian (\u003ci\u003eValeriana officinalis\u003c\/i\u003e), 387\u003c\/p\u003e \u003cp\u003eConclusion, 388\u003c\/p\u003e \u003cp\u003eReferences, 389\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 16 Psychopharmacology in Preschool Children, 399\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eMini Tandon \u0026amp; Joan Luby\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction, 399\u003c\/p\u003e \u003cp\u003eDevelopmental considerations, 400\u003c\/p\u003e \u003cp\u003eRise in psychopharmacology use, 402\u003c\/p\u003e \u003cp\u003ePsychotherapy before psychopharmacology, 403\u003c\/p\u003e \u003cp\u003eWhen psychopharmacology may be considered as a first line: pragmatic considerations, 404\u003c\/p\u003e \u003cp\u003ePsychopharmacology in preschool disorders: administration and monitoring, 404\u003c\/p\u003e \u003cp\u003eOff-label prescribing: special considerations, 407\u003c\/p\u003e \u003cp\u003eUse of psychotropics in specific disorders, 408\u003c\/p\u003e \u003cp\u003eSummary, 415\u003c\/p\u003e \u003cp\u003eReferences, 415\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 17 Combination Pharmacotherapy for Psychiatric Disorders in Children and Adolescents, 421\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eGagan Joshi \u0026amp; Anna M. Georgiopoulos\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eBipolar disorder, 422\u003c\/p\u003e \u003cp\u003eMajor depressive disorder, 429\u003c\/p\u003e \u003cp\u003eAttention-deficit hyperactivity disorder, 431\u003c\/p\u003e \u003cp\u003eObsessive-compulsive disorder, 433\u003c\/p\u003e \u003cp\u003eTics and Tourette's syndrome, 434\u003c\/p\u003e \u003cp\u003ePervasive developmental disorders, 434\u003c\/p\u003e \u003cp\u003eConclusion, 434\u003c\/p\u003e \u003cp\u003eReferences, 435\u003c\/p\u003e \u003cp\u003eIndex, 439\u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Other branches of medicine [\u003ca title=\"See our other books on Other branches of medicine\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Other%20branches%20of%20medicine%20%5BMM%5D%22\"\u003eMM\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Brand New","offer_id":52278162817304,"sku":"9780470973769","price":67.69,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/files\/9780470973769.jpg?v=1781458729","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/pharmacotherapy-of-child-and-adolescent-psychiatric-disorders-hardback-9780470973769","provider":"Freshly Printed Books","version":"1.0","type":"link"}